Metabolic dysfunction-associated steatotic liver

disease (MASLD) is strongly associated with heart failure with

preserved ejection fraction (HFpEF), driven by systemic inflammation,

insulin resistance, and oxidative stress, which are shared

pathophysiological mechanisms. HFpEF and MASLD often co-occur,

especially in patients with conditions like obesity and type 2

diabetes mellitus (T2DM). The increasing global prevalence of both

MASLD and HFpEF emphasises their shared risk factors and clinical

implications. Early diagnosis and a multidisciplinary approach

are important in the management of these interconnected diseases.

Treatment strategies like the use of sodium-glucose cotransporter-2

inhibitors (SGLT-2i) have shown promise in addressing both

conditions, improving liver steatosis, and reducing heart failure

risk. Targeted therapies and lifestyle modifications are fundamental

to managing MASLD and HFpEF, given their overlapping pathophysiology

and impact on patient outcomes.